Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

19 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

Eligibility NCT00689936 Multiple Myeloma - Eligibility

- 20-09-21 - 1 Formulier, 2 Itemgroepen, 47 Data-elementen, 2 Talen
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00689936

Eligibility NCT00777998 Multiple Myeloma - Eligibility

- 16-04-14 - 1 Formulier, 2 Itemgroepen, 10 Data-elementen, 2 Talen
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00408746

Eligibility NCT00722566 Multiple Myeloma - Eligibility

- 15-04-14 - 1 Formulier, 2 Itemgroepen, 11 Data-elementen, 2 Talen
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00722566

Eligibility NCT00915252 Acute Myeloid Leukemia - Eligibility

- 20-09-21 - 1 Formulier, 2 Itemgroepen, 24 Data-elementen, 2 Talen
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00915252

Eligibility NCT00560794 Acute Lymphoblastic Leukemia - Eligibility

- 20-09-21 - 1 Formulier, 2 Itemgroepen, 24 Data-elementen, 2 Talen
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00560794

Eligibility DRKS00000733 NCT00867672 Acute Myeloid Leukemia - Eligibility

- 20-09-21 - 1 Formulier, 2 Itemgroepen, 19 Data-elementen, 2 Talen
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00867672

dbGaP phs001066 DNA and RNA Sequence of an Acute Lymphoblastic Leukemia - pht005280.v1.p1

- 23-06-23 - 4 Formulieren, 1 Itemgroep, 3 Data-elementen, 1 Taal
Itemgroep: pht005280
Principal Investigator: Richard K. Wilson, PhD, McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO, USA MeSH: Neoplasms,Leukemia https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001066 We used massively parallel sequencing technology to profile the genomic DNA and RNA of tumor cells (leukemic bone marrow) and normal cells (skin biopsy) obtained from a single patient with Acute Lymphoblastic Leukemia (ALL), referred to throughout this study as 'ALL1'. Included in this study are samples obtained from a primary tumor, first relapse, second relapse and several intermediate timepoints. We identified somatic mutations present in each tumor by analysis of whole genome (WGS) and exome sequence data. Single nucleotide variants (SNVs) and small insertions and deletions were identified in both the exome and WGS data. Large copy number variations (CNVs) and structural variants (SVs) were identified in the WGS data. A custom capture reagent was designed to target most variants and used to generate deep validation sequence data. The expression status of all somatic variants was assessed by RNA-seq. The RNA-seq data was also used for gene expression analysis and gene fusion detection.

pht005281.v1.p1

1 Itemgroep 3 Data-elementen

pht005282.v1.p1

1 Itemgroep 2 Data-elementen

pht005283.v1.p1

1 Itemgroep 5 Data-elementen

Eligibility Advanced Cancers NCT01444716

- 09-05-16 - 1 Formulier, 2 Itemgroepen, 10 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Phase II Study of Ofatumumab in Elderly Patients With Chronic Lymphocytic Leukemia (CLL); ODM derived from: https://clinicaltrials.gov/show/NCT01444716

Eligibility NCT00684619 T-ALL, T-NHL (Lymphoblastic) - Eligibility

- 09-12-13 - 1 Formulier, 2 Itemgroepen, 15 Data-elementen, 2 Talen
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00684619

Eligibility NCT00053768 NHL - Eligibility

- 17-09-21 - 1 Formulier, 3 Itemgroepen, 33 Data-elementen, 2 Talen
Itemgroepen: Disease characteristics, Patient characteristics and prior concurrent therapy, Medical Concepts
Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma DISEASE CHARACTERISTICS: - Histologically confirmed aggressive non-Hodgkin's lymphoma - Previously untreated disease - Favorable prognosis - International Prognostic Index score of 0-1 - No more than 25% marrow involvement PATIENT CHARACTERISTICS: Age - 18 to 60 Performance status - ECOG 0-3 OR - Karnofsky 40-100% Life expectancy - Not specified Hematopoietic - Platelet count at least 100,000/mm^3 - WBC at least 2,500/mm^3 Hepatic - No active hepatitis infection Renal - Not specified Other - HIV negative - Not pregnant or nursing - No relevant accompanying disease - No other concurrent malignancy - No contraindications to any study medications - No prior noncompliance by patient PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - No prior chemotherapy Endocrine therapy - Not specified Radiotherapy - No prior radiotherapy Surgery - Not specified Other - No other concurrent participation in another treatment study

Eligibility NCT00785330 Non-Hodgkin's Lymphoma - Eligibility

- 09-12-13 - 1 Formulier, 2 Itemgroepen, 11 Data-elementen, 2 Talen
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00785330

dbGaP phs000559 PAGE: Epidemiologic Architecture for Genes Linked to Environment (EAGLE) - BioVU Cancer Project - Eligibility

- 12-12-22 - 5 Formulieren, 1 Itemgroep, 20 Data-elementen, 1 Taal
Itemgroep: IG.elig
Principal Investigator: Dana Crawford, PhD, Vanderbilt University, Nashville, TN, USA MeSH: Neoplasms,Breast Neoplasms,Colorectal Neoplasms,Endometrial Neoplasms,Lung Neoplasms,Lymphoma, Non-Hodgkin,Ovarian Neoplasms,Melanoma,Prostatic Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000559 As part of Population Architecture using Genomics and Epidemiology PAGE study (Phase I), the Epidemiologic Architecture using Genomics and Epidemiology (EAGLE I) project accessed both epidemiologic- and clinic-based collections. The epidemiologic-based collection of EAGLE I included the National Health and Nutritional Examination Surveys (NHANES), ascertained between 1991-1994 (NHANES III), 1999-2002, and 2007-2008. NHANES is a population-based cross-sectional survey now conducted every year in the United States to assess the health status of Americans at the time of ascertainment and to assess trends over the years of survey. Genetic NHANES consists of 19,613 DNA samples linked to thousands of variables including demographics, health and lifestyle variables, physical examination variables, laboratory variables, and exposures. NHANES is diverse with almost one-half of the samples (46.4%) coming from self-reported Mexican Americans and non-Hispanic blacks. In contrast to NHANES, BioVU is a clinic-based collection of 150,000 DNA samples from Vanderbilt University Medical Center linked to de-identified electronic medical records (EMRs). Approximately 12% of BioVU's overall DNA sample collection is from African American, Hispanic, and Asian patients. The overall goals of PAGE I and EAGLE I were broad and several-fold:- Replicate genome-wide association study (GWAS)- identified variants in European Americans; - Identify population-specific and trans-population genotype-phenotype associations; - Identify genetic and environmental modifiers of these associations. NHANES is an excellent resource for the study of quantitative traits associated with common human diseases. However, given that the age range of NHANES spans childhood to late adulthood and not all diseases are surveyed, NHANES is less useful for the study of adult-onset diseases such as major cancers. Therefore, under American Recovery and Reinvestment Act (ARRA) funding, EAGLE as part of PAGE I defined eight major cancers sites for genetic analysis in BioVU, Vanderbilt's biorepository linked to de-identified EMRs. The eight major cancers defined for this study included melanoma, breast, ovarian, prostate, colorectal, lung, endometrial, and Non-Hodgkin's lymphoma (NHL). Cancer cases were defined using a combination of ICD-9 codes and tumor registry entries. Controls include BioVU participants without cancer and encompassing the age and gender distributions of cancer cases. Targeted genotyping of GWAS-identified variants for these diseases (124 SNPs) and ancestry informative markers (128 AIMs) was performed by the Center for Human Genetics Research Vanderbilt DNA Resources Core. After quality control, a total of 116 cancer-associated SNPs and 122 AIMs were available for downstream analyses.

pht003614.v1.p1

1 Itemgroep 2 Data-elementen

pht003615.v1.p1

1 Itemgroep 3 Data-elementen

pht003616.v1.p1

1 Itemgroep 58 Data-elementen

pht003617.v1.p1

1 Itemgroep 5 Data-elementen

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial